Wiseheart Medval
Latest round
- Series A
Last raised
- Jan 2026
Total raised
- Undisclosed
Investors
- 3
About Wiseheart Medval
, Ltd, trading under the name Wiseheart Medval, operates as a biopharmaceutical company, focusing on cell therapy for neurological diseases. The company built a GMP-grade cell product manufacturing plant in Beijing's Zhongguancun Life Science Park. It has cooperated with Xuanwu Hospital. The company uses reprogramming technology and non-integrating systems to obtain neural stem cells (iNSC) directly induced from human peripheral blood single nucleated cells or fibroblasts, and simultaneously and directionally differentiate them into dopaminergic neural precursor cells (iNSC-DAP). Its core products, Dopaminergic Neural Precursor Cells (iNSC-DAP) Injection, can treat Parkinson's disease with clinical intervention through stereotactic transplantation clinical technology. This technology allows for autologous or allogeneic cell therapy, avoiding the ethical issues involved in embryonic stem cell harvesting. The company’s revenue is generated by the research, development, and commercialization of cell therapy drugs and regenerative medicine technologies.
Who invested in Wiseheart Medval
3 investors across 2 rounds
See all investors in Wiseheart Medval
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Wiseheart Medval
Who invested in Wiseheart Medval?
Wiseheart Medval has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Wiseheart Medval raised?
Wiseheart Medval has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Wiseheart Medval last raise money?
Wiseheart Medval's most recent round on record is a Series A, in Jan 2026.
What does Wiseheart Medval do?
, Ltd, trading under the name Wiseheart Medval, operates as a biopharmaceutical company, focusing on cell therapy for neurological diseases.
Where is Wiseheart Medval headquartered?
Wiseheart Medval is headquartered in Beijing, China.
Which VCs invest in companies like Wiseheart Medval?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Wiseheart Medval's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Wiseheart Medval? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.